|
|
|
|
Statins for high cholesterol - [Medication] - Quest Diagnostics Patient Health Library
Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Statins for high cholesterol - [Medication] - Quest Diagnostics Patient Health Library Statins for high cholesterol - [Medication] - Quest Diagnostics Patient Health Library Blood and lymph, Disease and injury prevention, Heart and circulation,...
|
|
|
http://www.biosis.org/ts/media/cdjournals/gazettenews/2002/CPG_News_0223.pdf
week 0223 7 June 2002 A cluster of four new applications from Kyorin can be seen this week relating to PPAR!"modulators.
(see page 12) ISSN:1464-3499 Drug Patenting in Context connotations is implied by a joint application naming Karo Bio AB and Abbott, relating to a type II diabetes discovery project.
These include Teva's continuing series on calcium salts and crystal...
|
|
|
bfw07182005.qxd page 2
author: RobbinsJ
|
|
|
Pfizer begins drug production in search of cardio cure
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
AstraZeneca Second Quarter Results 2003-General Presentation
Lipitor ® across the dose range b Significantly greater increases in HDL-C levels b Crestor ® 10mg gets significantly more patients to European LDL-C goal than atorvastatin 10mg (82% vs.
51%) b Data presented at ACC March 03 – Efficacy of Crestor ® vs other statins by dose – Efficacy of Crestor ® when switched from other statin therapy A...
|
|
|
NABI 10-K 03.23.05
Currently, the phosphate binder market in the five largest European markets exceeds 200 million Euros and is primarily served by Renagel (sevelamer hydrochloride) as well as a number of calcium acetate and calcium carbonate products.
During 2004 we initiated the CARE 2 study that will compare the efficacy, safety and arterial calcification in patients treated with...
author: bradleylewthwaite
|
|
|
NABI 10-K 03.23.05 page 43
author: bradleylewthwaite
|
|
|
NABI 10-K 03.23.05 page 10
author: bradleylewthwaite
|
|
|
BIOTECanada - Member News
Welcome to the new Member News Archives.
6) – Health Canada approved Pfizer Canada Inc.’s cholesterol-lowering therapy Lipitor(R) (atorvastatin calcium).
The decision was based on the findings of the landmark ASCOT trial(Anglo-Scandinavian Cardiac Outcomes Trial), which found that the lowest dose of Lipitor (10 mg) reduced the relative risk of...
|
|
|
Paragraph IV Patent Certifications
- DRUG NAME DOSAGE FORM STRENGTH RLD Acetaminophen Extended-release Tablets 650 mg Tylenol Acetaminophen/ Aspirin/ Caffeine Tablets 250 mg/250 mg/ 65 mg Excedrin (migraine) Acetaminophen and Tramadol Hydrochloride Tablets 325 mg/ 37.5 mg Ultracet Acyclovir Sodium1 Injection 50 mg/mL, 10 mL and 20 mL vials Zovirax Albuterol Sulfate Oral Syrup 2 mg(base)/ 5 mL Ventolin Albuterol...
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
ACTHAR GEL, CORTICOTROPIN H.R.-50, HYDROCHLOROTHIAZIDE HABITROL, NICOTINE (OTC) HALCION, TRIAZOLAM HALDOL SOLUTAB, HALOPERIDOL HALDOL, HALOPERIDOL HALDOL, HALOPERIDOL DECANOATE HALDOL, HALOPERIDOL LACTATE HALDRONE, PARAMETHASONE ACETATE HALFAN, HALOFANTRINE HYDROCHLORIDE HALOG, HALCINONIDE HALOG-E, HALCINONIDE HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE HALOPERIDOL INTENSOL,...
|
|
|
1998 Warning Letters and Untitled Letters to Pharmaceutical Companies
Food and Drug Administration • Center for Drug Evaluation and Research Compliance Activities Search Warning Letters and Untitled Letters to Pharmaceutical Companies 1998 These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office
DDMAC 4/27 5/7 MUSE (alprostadil) urethral suppository Vivus DDMAC 4/1 4/9 Nicotrol Inhaler (nicotine)...
|
|
|
2002 Warning Letters and Untitled Letters to Pharmaceutical Companies
Food and Drug Administration • Center for Drug Evaluation and Research Compliance Activities Search Warning Letters and Untitled Letters to Pharmaceutical Companies 2002 These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office
The letters are arranged in chronological order by month.- Click on the month to view the letters in Adobe...
author: STAUFFERP
|
|
|
20-702S025_Lipitor
Food and Drug Administration • Center for Drug Evaluation and Research Title Search Lipitor (Atorvastatin Calcium) Tablets Company:--Pfizer Ireland Pharmaceuticals Application No.:--20-702/S25 Approval Date:-6/15/2001 Approval Letter(s) - Printed Labeling - Medical Review(s) - Chemistry Review(s) - Statistical Review(s) - Administrative Document(s) - - Back to...
author: USERNAME
|
|
|
Microsoft Word - Medication_Listing.doc
10 mg tab – Autosubstitution to benazepril (ASL- 02) Continuing Care Pharmacy & Therapeutics Formulary ML- 01 SECTION SUBJECT Page 9 of 38 MEDICATION LISTING (ML) Medication Listing YY MM DD Original 00 10 30 Revised 02 01 14 Revised 03 10 23 digoxin (Lanoxin®) 0.0625 mg, 0.125 mg, 0.25 mg tab 0.05 mg/ mL oral liquid diltiazem (Cardizem®/ Tiazac®) 30 mg, 60 mg tab...
author: Wendy Daws
|
|
|
Microsoft Word - Medication_Listing.doc page 11
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc
Continuing Care Pharmacy & Therapeutics Formulary ML- Index SECTION SUBJECT Page 1 of 58 MASTER INDEX Medication Listing Index YY MM DD Original 00 10 30 Revised 01 12 19 Revised 03 10 23 DRUG NAME PAGE CLASS 5- FU Refer to Province Wide Services (PWS- 02) 35 84: 36 Abenol® 14 28: 08.92 Accupril® Restricted Status (RS- 08), Autosubstitution to benazepril or captopril (ASL-...
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc page 4
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc page 4
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc
Continuing Care Pharmacy & Therapeutics Formulary ML- Index SECTION SUBJECT Page 1 of 58 MASTER INDEX Medication Listing Index YY MM DD Original 00 10 30 Revised 01 12 19 Revised 03 10 23 DRUG NAME PAGE CLASS 5- FU Refer to Province Wide Services (PWS- 02) 35 84: 36 Abenol® 14 28: 08.92 Accupril® Restricted Status (RS- 08), Autosubstitution to benazepril or captopril (ASL-...
author: Wendy Daws
|
|
|
C:\Data\My Documents\NDA\N21073S20AP.doc
4 ACTOS ® (pioglitazone hydrochloride) Tablets DESCRIPTION ACTOS (pioglitazone hydrochloride) is an oral antidiabetic agent that acts primarily by decreasing insulin resistance
ACTOS is available as a tablet for oral administration containing 15 mg, 30 mg, or 45 mg of pioglitazone (as the base) formulated with the following excipients: lactose monohydrate NF,...
author: Jena Weber
|
|
|
C:\Data\My Documents\NDA\N21073S20AP.doc page 4
author: Jena Weber
|
|
|
Reference Listed Drug Labeling Approved in June 2001
Jun 1 CEFAZOLIN AND DEXTROSE letter label cefazolin for injection/dextrose injection 50-779 S-001 Jun 5 LIMBITROL DS letter label chlordiazepoxide/amitriptyline HCl tablets 16-949 S-033 ZEMURON letter label rocuronium bromide injection 20-214 S-013 Jun 6 MENTAX letter label butenafine HCl cream 20-524 S-005 Jun 8 INTEGRILIN letter label eptifibatide injection 20-718 S-013 LIPITOR...
author: USERNAME
|
|
|
Atazanavir
AVOID: Simvastatin (ZOCOR), Lovastatin (MEVACOR), St.John’s Wart (Hypericum perforatum), Rifampin , Ergot medications , Triazolam (HALCION), Midazolam (VERSED), Pimozide, Indinavir, Irinotecan, Bepridil, Proton pump inhibitors (omeprazole-LOSEC, lansoprazole-PREPULSID, pantoprazole-PANTOLOC, esomeprazole-NEXIUM) Caution: Rifabutin (MYCOBUTIN), Sildenafil (VIAGRA), ...
|
|
|
Lipitor (atorvastatin calcium) Approval Package
Food and Drug Administration • Center for Drug Evaluation and Research Approval Package Search Lipitor Tablets (atorvastatin calcium) Company:- Parke-Davis Pharmaceutical Research Application No.:- 020702, S018 Approval Date:-12/02/99 Approval Letter(s) - Printed Labeling -- Medical Review(s) - Chemistry Review(s) - Pharmacology Review(s) - Statistical Review(s...
author: USERNAME
|
